Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MetRx "andro" ads

This article was originally published in The Tan Sheet

Executive Summary

MetRx revising ads for its fitness supplements to delete products containing androstenedione after ESPN and Fox Sports pulled the original ads in response to public outcry. The new ads are slated to air in late October. The controversy over the use of androstenedione is due to questions regarding its steroid nature and unknown side effects. MetRx is conducting several studies at Eastern Michigan University to determine the testosterone-related effects of androstenedione. In the first of five studies, the company is dosing eight male college-age subjects on a rotating basis with either placebo, 100 mg androstenedione or 100 mg androstenediol, a similar substance, with a three-day washout period between treatments, then comparing blood levels of testosterone to baseline at various points up to 90 minutes post-dose. MetRx says androstenediol is three times more potent than androstenedione. Testosterone levels for all subjects have remained within normal physiological levels
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel